
WHAT IS CLAIMED IS:

1. 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-*N*-ethyl-hept-5-enamide having the structure



in crystalline form II.

2. A crystalline form of 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-*N*-ethyl-hept-5-enamide having an X-ray powder diffraction pattern with peaks at about (2θ): 3.60, 5.31, 7.09, 10.55, 12.24, 13.29, 14.55, 15.85, 17.60, 18.49, 19.00, 19.65, 21.10, 22.20, 22.69, 24.75 and ~~26~~28.65.

3 The crystalline form of claim 1 having the X-ray diffraction pattern substantially as shown in Fig. **2**.

4. The crystalline form of claim 1 having an ~~exothermic~~ endothermic onset at about 70.~~1~~9 °C and a peak at 74.~~1~~5 °C in its differential scanning calorimetry profile.

5. The crystalline form of claim 1 having the DSC profile as shown in Fig. **1**.

6. A pharmaceutical composition comprising a therapeutically effective amount of 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-*N*-ethyl-hept-5-enamide crystalline form II in an ophthalmically acceptable carrier therefore.

7. Use of 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-*N*-ethyl-hept-5-enamide in crystalline form II in an ophthalmically acceptable carrier, in the manufacture of a medicament for the treatment of ocular hypertension.

8. The use of claim 7 wherein the ophthalmically acceptable carrier is selected from the group consisting of ophthalmically acceptable diluents, buffers, hydrochloric acid, sodium hydroxide, preservatives, stabilizers, tonicity adjustors, viscosity-enhancing agents, chelating agents, surfactants and/or solubilizers and combinations thereof.

9. Use of 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-*N*-ethyl-hept-5-enamide in crystalline form II in an ophthalmically acceptable carrier, in the manufacture of medicament for the treatment of glaucoma.

10. The crystalline form of claim 1 ~~substantially~~ free of other crystalline forms.

11. A method for converting 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-*N*-ethyl-hept-5-enamide in crystalline form I to crystalline form II comprising:

a) heating 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-*N*-ethyl-hept-5-enamide in crystalline form I in the solid state from about 55 °C to about 72 °C at a heating rate of about 2 °C per minute;

b) cooling the crystalline 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-*N*-ethyl-hept-5-enamide from about 72 °C to about 55 °C at a cooling rate of about 0.2-0.5 °C per minute;

c) repeating steps a) and b) from 3 to about 9 times;

thereby converting crystalline form I to crystalline form II.